



DFW

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/632,706	
	Filing Date	August 1, 2003	
	First Named Inventor	James D. Marks	
	Group Art Unit	1645	
	Examiner Name	Virginia Allen Portner	
Total Number of Pages in This Submission		Attorney Docket Number	407T-895120US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Terminal Disclaimer	64 Enclosed References receipt acknowledgment postcard
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Small Entity Statement	
	<input type="checkbox"/> Request for Refund	
Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Tom Hunter, Reg. No. 38,498, Quine Intellectual Property Law Group P.C.
Signature	
Date	May 16, 2005

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DC 20231 on this date: May 16, 2005			
Typed or printed name	Chianti Appling		
Signature		Date	5/16/05



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on May 16, 2005

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By

Chianti Appling

Attorney Docket No. 407T-895120US
Client Ref. No. 1998-013-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

James D. Marks, et al.

Application No.: 10/632,706

Filed: August 1, 2003

For: THERAPEUTIC MONOCLONAL
ANTIBODIES THAT NEUTRALIZE
BOTULINUM NEUROTOXINS

Confirmation No. 5306

Examiner: Virginia Allen Portner

Art Unit: 1645

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Tom Hunter', with a stylized flourish extending to the right.

Tom Hunter, J.D., Ph.D.
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

MAY 18 2005

(use as many sheets as necessary)

Application Number	10/632,706
Filing Date	August 1, 2003
First Named Inventor	James D. Marks
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	407T-895120US
Date Submitted	May 16, 2005

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1.	4,689,299		Insel et al.	08/25/1987	
	2.	5,306,730		Nagai et al.	04/26/1994	
	3.	5,807,741		Brown et al.	9/15/1998	
	4.	5,919,665		Williams	07/06/1999	
	5.	5,932,449		Emanuel et al.	8/3/1999	
	6.	6,331,402		Nussbaum et al.	12/18/2001	
	7.	6,416,947		Balasubramanian et al.	07/09/2002	
	8.	6,495,143		Lee et a.	12/17/2002	
	9.	6,667,158		Bavari et al.	12/23/2003	
	10.	6,841,156		Aoki et al.	01/11/2005	
	11.	2002/0155114		Marks	10/24/2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	12.	WO	00/69891		Dept of the Army	11/23/2000		
	13.	WO	00/69895		Dept of the Army	11/23/2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	14.	Amersdorfer et al. (1997) <i>Infect. Immun.</i> , 65: 3743-3752	
	15.	Amersdorfer et al. (2002) <i>Vaccine</i> 20: 1640-1648	
	16.	Arnon (1993) Pp. 477-482 in <i>Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects</i> , ed. DasGupta, B. R. Plenum, New York	
	17.	Arnon et al. (2001) <i>J. Am. Med. Assoc.</i> 285: 1059-1070	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/632,706
	Filing Date	August 1, 2003
	First Named Inventor	James D. Marks
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	407T-895120US
	Date Submitted	May 16, 2005

18.	Atassi (1996) <i>J. Protein Chem.</i> , 15: 691-699	
19.	Atassi (1996) <i>J. Protein Chem.</i> , 15: 691-699	
20.	Black and Gunn. (1980) <i>Am. J. Med.</i> , 69: 567-570	
21.	Black, <i>et al.</i> (1980) <i>Am. J. Med.</i> , 69:567-570	
22.	Black, <i>et al.</i> (1986) <i>J. Cell Biol.</i> , 103:521-534	
23.	Bowmer (1963) <i>Bull. W. H. O.</i> 29: 701-709	
24.	Byrne and Smith (2000) <i>Biochimie</i> 82: 955-966	
25.	Chen et al. (1997) <i>Infect. Immun.</i> 65(5): 1626-1630	
26.	Chen et al. (1998) <i>Infect. Immun.</i> , 66: 2420-2425	
27.	Colcher <i>et al.</i> (1990) <i>J. Natl. Cancer Inst.</i> 82: 1191-1197	
28.	Daniels-Holgate <i>et al.</i> (1996) <i>J. Neurosci. Res.</i> 44:263-271	
29.	Demarchi, <i>et al.</i> (1958) <i>Bull. Acad. Nat. Med.</i> , 142: 580-582	
30.	Dolly <i>et al.</i> (1984) <i>Nature (London)</i> 307: 457-460	
31.	Emanuel <i>et al.</i> (1996) <i>J. Immunol. Meth.</i> , 193: 189-197	
32.	Fitzsimmons <i>et al.</i> (2000) <i>Vaccine</i> 19: 114-121	
33.	Foote and Milstein (1991) <i>Nature</i> , 352:530-532	
34.	Foote, <i>et al.</i> (1991) <i>Nature</i> 352: 530-532	
35.	Fotinou <i>et al.</i> (2001) <i>J. Biol. Chem.</i> 276: 32274-32281	
36.	Franz et al. (1993) Pp. 473-476 in <i>Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects</i> , ed. DasGupta, B. R. Plenum, New York	
37.	Gibson <i>et al.</i> (1988) <i>J. Appl. Bacteriol.</i> , 64: 285-291	
38.	Gill (1982) <i>Microbiol. Rev.</i> 46: 86-94	
39.	Hallis et al. (1993) Pp. 433-436 In: <i>Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects</i> , ed. DasGupta, B. R., Plenum, New York	
40.	Hathaway, <i>et al.</i> (1984) <i>J. Infect. Dis.</i> 150:407-412	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/632,706
	Filing Date	August 1, 2003
	First Named Inventor	James D. Marks
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	407T-895120US
	Date Submitted	May 16, 2005

41.	Hatheway (1995) <i>Curr. Top. Microbio. Immunol.</i> , 195: 55-75	
42.	Hatheway and Dang (1994) Pp. 93-107 In: <i>Therapy with Botulinum Toxin</i> , ed. Jankovic, J., Dekker, New York	
43.	Hatheway <i>et al.</i> (1984) <i>J. Infect. Dis.</i> , 150: 407-412	
44.	Hibbs <i>et al.</i> (1996) <i>Clin. Infect. Dis.</i> , 23: 337-340	
45.	Hildebrand, et al. (1961) <i>Proc. Soc. Exp. Biol. Med.</i> 107-284-289	
46.	Huston, et al.,(1996) <i>J. Nucl. Med.</i> 40: 320	
47.	Koriazova and Montal (2003) <i>Nat. Struct. Biol.</i> , 10: 13-18	
48.	Kozaki <i>et al.</i> (1986) <i>Infect. Immun.</i> , 52: 786-791	
49.	Kozaki et al. (1995) <i>Microbiol. Immunol.</i> , 39: 767-774	
50.	Kozaki <i>et al.</i> (1998) <i>Infect. Immun.</i> , 66: 4811-4816	
51.	Lacy and Stevens (1999) <i>J. Mol. Biol.</i> 291: 1091-1104	
52.	Lacy et al. (1998) <i>Nat. Struct. Biol.</i> 5: 898-902	
53.	Lang, et al. (1993) <i>J. Immunol.</i> 151: 466-473	
54.	Mahant et al. (2000) <i>J. Clin. Neurosci.</i> 7: 389-394	
55.	Middlebrook and Franz (1997) Botulinum Toxins, chapter 33. In F.R. Sidell, E.T. Takafuji, D.R. Franz (eds.), <i>Medical Aspects of Chemical and Biological Warfare</i> . TMM publications, Washington, D.C.	
56.	Middlebrook, et al. (1995) <i>Curr. Top. Microbiol. Immunol.</i> 195:89-122	
57.	Montecucco (1986) <i>Trends Biochem. Sci.</i> 11:314-317	
58.	Montecucco and Schiavo (1995) <i>Q. Rev. Biophys.</i> 28: 423-472	
59.	Montero-Julian <i>et al.</i> (1995) <i>Blood</i> 85: 917-924	
60.	Mullaney <i>et al.</i> (2001) <i>Infect. Immun.</i> 69: 6511-6514	
61.	Nowakowski <i>et al.</i> (2002) <i>Proc. Natl. Acad. Sci. U S A</i> , 99: 11346-11350	
62.	Oguma <i>et al.</i> (1990) <i>Lancet</i> 336: 1449-1450	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/632,706
	Filing Date	August 1, 2003
	First Named Inventor	James D. Marks
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	407T-895120US
	Date Submitted	May 16, 2005

63.	Pless et al. (2001) <i>Infect. Immun.</i> 69: 570-574	
64.	Reichert (2001) <i>Nat. Biotechnol.</i> 19: 819-822	
65.	Schengrund (1999) <i>J Toxicol Toxin Rev.</i> , 18: 35-44	
66.	Schiavo et al. (1992) <i>Nature (London)</i> 359: 832-835	
67.	Schiavo et al. (1993) <i>J. Biol. Chem.</i> 268: 23784-23787	
68.	Schier et al. (1995) <i>Immunotechnology</i> , 1: 73-81	
69.	Siegel (1988) <i>J. Clin. Microbiol.</i> 26: 2351-2356	
70.	Simpson (1980) <i>J. Pharmacol. Exp. Ther.</i> 212: 16-21	
71.	Sonnabend et al. (1981) <i>J. Infect. Dis.</i> , 143: 22-27	
72.	Tacket et al. <i>Am. J. Med.</i> , 76: 794-798	
73.	Volk et al. (1984) <i>Infect. Immun.</i> 45: 604-609	
74.	Williams et al. (1983) <i>Eur. J. Biochem.</i> , 131: 437-445	
75.	Zwick et al. (2001) <i>J. Virol.</i> 75: 12198-12208	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.